AST-030

AST-030 is an investigational small molecule drug candidate being developed by Astrogen, a South Korean biopharmaceutical company specializing in neurological and intractable disorders. The drug is currently in early-stage development for two primary indications: Parkinson's Disease (PD) and Idiopathic Pulmonary Fibrosis (IPF). While the specific molecular target of AST-030 has not been publicly disclosed in detail, it is part of a pipeline that focuses on addressing mitochondrial dysfunction and cellular stress pathways common to both neurodegenerative and fibrotic pathologies. AST-030 aims to provide neuroprotective effects in PD and anti-fibrotic activity in IPF, representing a multi-indication approach to diseases characterized by progressive cellular decline.